Merck is seeking approval for additional uses of its diabetes drug Januvia and hopes for an FDA decision by mid-October. Merck wants the drug cleared for use in three approaches to improving glycemic control.
Published in Brief:
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||